S 777469
Alternative Names: S-777469Latest Information Update: 02 Oct 2021
At a glance
- Originator Shionogi
- Class Anti-inflammatories; Antipruritics
- Mechanism of Action Cannabinoid receptor CB2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atopic dermatitis
Most Recent Events
- 28 Nov 2008 Phase-II clinical trials in Atopic dermatitis in Japan (PO)
- 28 Nov 2008 Phase-II clinical trials in Atopic dermatitis in USA (PO)
- 19 Feb 2007 Phase-I clinical trials in Atopic dermatitis in Japan (PO)